British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU’s pharmaceuticals industry risks forcing companies to invest and innovate elsewhere, which would hurt EU efforts to improve access to medicines.

Cannabis products, excluding Jazz Pharmaceuticals Plc’s epilepsy drug Epidiolex, are illegal at the federal level in the United States, although some states allow their use.